Samantha G. Pattenden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samantha G. Pattenden has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Charlene Santos
21 shared publicationsDaniel R. Goulet
21 shared publicationsDarshan Singh
21 shared publications- Gary L. Johnson
University of North Carolina at Chapel Hill 1 Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
21 shared publications Ian J. Davis
21 shared publicationsJon S. Zawistowski
21 shared publications
Latest Publications
- 2 July 2026
- Published by Springer Nature
- p. 417-432
The High-Throughput C-Circle Assay for Identifying Modulators of Alternative Lengthening of Telomeres(ALT) Activity
- 2 July 2026
- Published by Springer Nature
- p. 417-432
The High-Throughput C-Circle Assay for Identifying Modulators of Alternative Lengthening of Telomeres(ALT) Activity
- Open Access
- 17 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341139
96 sample parallel acoustic fragmentation for high throughput next generation sequencing library preparation
Random, unbiased fragmentation of genomic DNA is necessary for next generation sequencing (NGS), yet the process of DNA fragmentation is still a bottleneck in NGS pipelines. A technology that increases the efficiency and consistency of this step will be highly desirable for both research laboratories and in clinical diagnostics. Previously, we reported the development of a novel cavitation enhancement reagent that dramatically decreases the time and acoustic energy required for genomic DNA fragmentation. The inclusion of this reagent in standard protocols facilitates highly efficient sonication enabling the use of widely available and inexpensive equipment, including water bath-based sonicators. Here, we report that cavitation enhancement facilitates parallel fragmentation of up to 96 samples of genomic DNA in a modified sonication device. The parallel processing of multiple samples significantly reduces processing time, while maintaining fragment range reproducibility and preserving DNA quality for NGS. Consequently, this system removes a key bottleneck in standard NGS pipelines and facilitates efforts toward research and personalized genomics.
- 17 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0341139
Open Access96 sample parallel acoustic fragmentation for high throughput next generation sequencing library preparation
Random, unbiased fragmentation of genomic DNA is necessary for next generation sequencing (NGS), yet the process of DNA fragmentation is still a bottleneck in NGS pipelines. A technology that increases the efficiency and consistency of this step will be highly desirable for both research laboratories and in clinical diagnostics. Previously, we reported the development of a novel cavitation enhancement reagent that dramatically decreases the time and acoustic energy required for genomic DNA fragmentation. The inclusion of this reagent in standard protocols facilitates highly efficient sonication enabling the use of widely available and inexpensive equipment, including water bath-based sonicators. Here, we report that cavitation enhancement facilitates parallel fragmentation of up to 96 samples of genomic DNA in a modified sonication device. The parallel processing of multiple samples significantly reduces processing time, while maintaining fragment range reproducibility and preserving DNA quality for NGS. Consequently, this system removes a key bottleneck in standard NGS pipelines and facilitates efforts toward research and personalized genomics.
- Open Access
- 7 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0340374
GelInsight: Open-source software for large-sample DNA fragmentation quality control in gel electrophoresis images
High throughput DNA fragmentation technology for next generation sequencing have become widely available, but there remains a need for affordable and efficient DNA fragmentation pattern analysis. Commercial electrophoresis platforms, such as the TapeStation, are costly, time-consuming, and have limited batch-processing capabilities. Traditional gel electrophoresis provides a low-cost, high-throughput alternative. However, existing open-source software, such as ImageJ, for gel electrophoresis image analysis typically requires extensive manual pre-processing and yields limited quantitative metrics relevant to DNA fragmentation quality control. Here, we have developed an open-source MATLAB-based software, GelInsight , for bulk analysis of gel electrophoresis images for analysis and quality control of DNA fragmentation patterns. GelInsight integrates automated image and signal processing tools to determine the base pair size distribution of each sample and to calculate key quality control metrics, including multiple peak base pair sizes and base pair size percentage within a specified range. A user-friendly graphical user interface facilitates efficient data interaction and comprehensive visualization of the analytical outputs. The quantification accuracy of GelInsight , including peak base-pair accuracy and relative area measurements, is consistent with both existing open-source software (within 2 ± 2 bp) and commercial assays (within 64 ± 24 bp). Overall, this automated tool streamlines gel image analysis and enhances reproducibility and quantitative rigor in assessing DNA fragmentation patterns.
- 7 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0340374
Open AccessGelInsight: Open-source software for large-sample DNA fragmentation quality control in gel electrophoresis images
High throughput DNA fragmentation technology for next generation sequencing have become widely available, but there remains a need for affordable and efficient DNA fragmentation pattern analysis. Commercial electrophoresis platforms, such as the TapeStation, are costly, time-consuming, and have limited batch-processing capabilities. Traditional gel electrophoresis provides a low-cost, high-throughput alternative. However, existing open-source software, such as ImageJ, for gel electrophoresis image analysis typically requires extensive manual pre-processing and yields limited quantitative metrics relevant to DNA fragmentation quality control. Here, we have developed an open-source MATLAB-based software, GelInsight , for bulk analysis of gel electrophoresis images for analysis and quality control of DNA fragmentation patterns. GelInsight integrates automated image and signal processing tools to determine the base pair size distribution of each sample and to calculate key quality control metrics, including multiple peak base pair sizes and base pair size percentage within a specified range. A user-friendly graphical user interface facilitates efficient data interaction and comprehensive visualization of the analytical outputs. The quantification accuracy of GelInsight , including peak base-pair accuracy and relative area measurements, is consistent with both existing open-source software (within 2 ± 2 bp) and commercial assays (within 64 ± 24 bp). Overall, this automated tool streamlines gel image analysis and enhances reproducibility and quantitative rigor in assessing DNA fragmentation patterns.
- 8 September 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (10) , 3585-3599
A First-in-Class Chemical-Induced Proximity System Achieves Dose-Dependent Control of Tumor Protein P53 Gene Activation in Preclinical Models of Gastric Cancer
The tumor protein P53 (TP53) gene has long been studied in cancer research with genomic and epigenetic aberrations playing a driving role in cancer pathology, yet even after decades of work, only a few methods have been developed to specifically target TP53 therapeutically. Some cancers are driven by loss-of-function TP53 mutations, while others have wild-type TP53 in a transcriptionally repressed state; the latter is exploitable by advances in epigenome editing. In our previous work, we demonstrated that deactivated CRISPR/Cas9 systems (dCas9), combined with an FK-506-binding protein (FKBP) recruitment protein tag and chemical epigenetic modifier (CEM) small molecules, can elicit gene-specific changes in expression in a dose-dependent manner. Here, we describe the development, application, and characterization of the dCas9-FKBP-CEM technology to increase TP53 expression. We demonstrate that catalyzing increased TP53 expression via dCas9-FKBP-CEM87 induced apoptosis, cell cycle arrest, and tumor growth inhibition in a dose-dependent manner in preclinical models of gastric cancer.
- 8 September 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (10) , 3585-3599
A First-in-Class Chemical-Induced Proximity System Achieves Dose-Dependent Control of Tumor Protein P53 Gene Activation in Preclinical Models of Gastric Cancer
The tumor protein P53 (TP53) gene has long been studied in cancer research with genomic and epigenetic aberrations playing a driving role in cancer pathology, yet even after decades of work, only a few methods have been developed to specifically target TP53 therapeutically. Some cancers are driven by loss-of-function TP53 mutations, while others have wild-type TP53 in a transcriptionally repressed state; the latter is exploitable by advances in epigenome editing. In our previous work, we demonstrated that deactivated CRISPR/Cas9 systems (dCas9), combined with an FK-506-binding protein (FKBP) recruitment protein tag and chemical epigenetic modifier (CEM) small molecules, can elicit gene-specific changes in expression in a dose-dependent manner. Here, we describe the development, application, and characterization of the dCas9-FKBP-CEM technology to increase TP53 expression. We demonstrate that catalyzing increased TP53 expression via dCas9-FKBP-CEM87 induced apoptosis, cell cycle arrest, and tumor growth inhibition in a dose-dependent manner in preclinical models of gastric cancer.
- 13 August 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (9) , 2799-2819
A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway
Telomeres are a protective cap that prevents chromosome ends from being recognized as double-stranded breaks. In somatic cells, telomeres shorten with each cell division due to the end replication problem, which eventually leads to senescence, a checkpoint proposed to prevent uncontrolled cell growth. Tumor cells avoid telomere shortening by activating one of two telomere maintenance mechanisms (TMMs): telomerase reactivation or alternative lengthening of telomeres (ALT). TMMs are a viable target for cancer treatment as they are not active in normal, differentiated cells. Whereas there is a telomerase inhibitor currently undergoing clinical trials, there are no known ALT inhibitors in development, partially because the complex ALT pathway is still poorly understood. For cancers such as neuroblastoma and osteosarcoma, the ALT-positive status is associated with an aggressive phenotype and few therapeutic options. Thus, methods that characterize the key biological pathways driving ALT will provide important mechanistic insight. We have developed a first-in-class phenotypic high-throughput screen to identify small-molecule inhibitors of ALT. Our screen measures relative C-circle level, an ALT-specific biomarker, to detect changes in ALT activity induced by compound treatment. To investigate epigenetic mechanisms that contribute to ALT, we screened osteosarcoma and neuroblastoma cells against an epigenetic-targeted compound library. Hits included compounds that target chromatin-regulating proteins and DNA damage repair pathways. Overall, the high-throughput C-circle assay will help expand the repertoire of potential ALT-specific therapeutic targets and increase our understanding of ALT biology.
- 13 August 2024
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (9) , 2799-2819
A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway
Telomeres are a protective cap that prevents chromosome ends from being recognized as double-stranded breaks. In somatic cells, telomeres shorten with each cell division due to the end replication problem, which eventually leads to senescence, a checkpoint proposed to prevent uncontrolled cell growth. Tumor cells avoid telomere shortening by activating one of two telomere maintenance mechanisms (TMMs): telomerase reactivation or alternative lengthening of telomeres (ALT). TMMs are a viable target for cancer treatment as they are not active in normal, differentiated cells. Whereas there is a telomerase inhibitor currently undergoing clinical trials, there are no known ALT inhibitors in development, partially because the complex ALT pathway is still poorly understood. For cancers such as neuroblastoma and osteosarcoma, the ALT-positive status is associated with an aggressive phenotype and few therapeutic options. Thus, methods that characterize the key biological pathways driving ALT will provide important mechanistic insight. We have developed a first-in-class phenotypic high-throughput screen to identify small-molecule inhibitors of ALT. Our screen measures relative C-circle level, an ALT-specific biomarker, to detect changes in ALT activity induced by compound treatment. To investigate epigenetic mechanisms that contribute to ALT, we screened osteosarcoma and neuroblastoma cells against an epigenetic-targeted compound library. Hits included compounds that target chromatin-regulating proteins and DNA damage repair pathways. Overall, the high-throughput C-circle assay will help expand the repertoire of potential ALT-specific therapeutic targets and increase our understanding of ALT biology.
- Open Access
- 8 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1284535
Editorial: Epigenetic insights into diagnostic and therapeutic applications
Editorial: Epigenetic insights into diagnostic and therapeutic applications
- 8 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1284535
Open AccessEditorial: Epigenetic insights into diagnostic and therapeutic applications
Editorial: Epigenetic insights into diagnostic and therapeutic applications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer
Triple-negative breast cancers contain a spectrum of epithelial and mesenchymal phenotypes. SUM-229PE cells represent a model for this heterogeneity, maintaining both epithelial and mesenchymal subpopulations that are genomically similar but distinct in gene expression profiles. We identified differential regions of open chromatin in epithelial and mesenchymal cells that were strongly correlated with regions of H3K27ac. Motif analysis of these regions identified consensus sequences for transcription factors that regulate cell identity. Treatment with the MEK inhibitor trametinib induced enhancer remodeling that is associated with transcriptional regulation of genes in epithelial and mesenchymal cells. Motif analysis of enhancer peaks downregulated in response to chronic treatment with trametinib identified AP-1 motif enrichment in both epithelial and mesenchymal subpopulations. Chromatin immunoprecipitation sequencing (ChIP-seq) of JUNB identified subpopulation-specific localization, which was significantly enriched at regions of open chromatin. These results indicate that cell identity controls localization of transcription factors and chromatin-modifying enzymes to enhancers for differential control of gene expression. We identified increased H3K27ac at an enhancer region proximal to CXCR7, a G-protein–coupled receptor that increased 15-fold in expression in the epithelial subpopulation during chronic treatment. RNAi knockdown of CXCR7 inhibited proliferation in trametinib-resistant cells. Thus, adaptive resistance to chronic trametinib treatment contributes to proliferation in the presence of the drug. Acquired amplification of KRAS following trametinib dose escalation further contributed to POS cell proliferation. Adaptive followed by acquired gene expression changes contributed to proliferation in trametinib-resistant cells, suggesting inhibition of early transcriptional reprogramming could prevent resistance and the bypass of targeted therapy.Implications:We defined the differential responses to trametinib in subpopulations of a clinically relevant in vitro model of TNBC, and identified both adaptive and acquired elements that contribute to the emergence of drug resistance mediated by increased expression of CXCR7 and amplification of KRAS.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer
Triple-negative breast cancers contain a spectrum of epithelial and mesenchymal phenotypes. SUM-229PE cells represent a model for this heterogeneity, maintaining both epithelial and mesenchymal subpopulations that are genomically similar but distinct in gene expression profiles. We identified differential regions of open chromatin in epithelial and mesenchymal cells that were strongly correlated with regions of H3K27ac. Motif analysis of these regions identified consensus sequences for transcription factors that regulate cell identity. Treatment with the MEK inhibitor trametinib induced enhancer remodeling that is associated with transcriptional regulation of genes in epithelial and mesenchymal cells. Motif analysis of enhancer peaks downregulated in response to chronic treatment with trametinib identified AP-1 motif enrichment in both epithelial and mesenchymal subpopulations. Chromatin immunoprecipitation sequencing (ChIP-seq) of JUNB identified subpopulation-specific localization, which was significantly enriched at regions of open chromatin. These results indicate that cell identity controls localization of transcription factors and chromatin-modifying enzymes to enhancers for differential control of gene expression. We identified increased H3K27ac at an enhancer region proximal to CXCR7, a G-protein–coupled receptor that increased 15-fold in expression in the epithelial subpopulation during chronic treatment. RNAi knockdown of CXCR7 inhibited proliferation in trametinib-resistant cells. Thus, adaptive resistance to chronic trametinib treatment contributes to proliferation in the presence of the drug. Acquired amplification of KRAS following trametinib dose escalation further contributed to POS cell proliferation. Adaptive followed by acquired gene expression changes contributed to proliferation in trametinib-resistant cells, suggesting inhibition of early transcriptional reprogramming could prevent resistance and the bypass of targeted therapy.Implications:We defined the differential responses to trametinib in subpopulations of a clinically relevant in vitro model of TNBC, and identified both adaptive and acquired elements that contribute to the emergence of drug resistance mediated by increased expression of CXCR7 and amplification of KRAS.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer
Wild-type KRAS is Amplified in Trametinib Resistant POS Cells Following Dose Escalation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer
Wild-type KRAS is Amplified in Trametinib Resistant POS Cells Following Dose Escalation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer
Triple-negative breast cancers contain a spectrum of epithelial and mesenchymal phenotypes. SUM-229PE cells represent a model for this heterogeneity, maintaining both epithelial and mesenchymal subpopulations that are genomically similar but distinct in gene expression profiles. We identified differential regions of open chromatin in epithelial and mesenchymal cells that were strongly correlated with regions of H3K27ac. Motif analysis of these regions identified consensus sequences for transcription factors that regulate cell identity. Treatment with the MEK inhibitor trametinib induced enhancer remodeling that is associated with transcriptional regulation of genes in epithelial and mesenchymal cells. Motif analysis of enhancer peaks downregulated in response to chronic treatment with trametinib identified AP-1 motif enrichment in both epithelial and mesenchymal subpopulations. Chromatin immunoprecipitation sequencing (ChIP-seq) of JUNB identified subpopulation-specific localization, which was significantly enriched at regions of open chromatin. These results indicate that cell identity controls localization of transcription factors and chromatin-modifying enzymes to enhancers for differential control of gene expression. We identified increased H3K27ac at an enhancer region proximal to CXCR7, a G-protein–coupled receptor that increased 15-fold in expression in the epithelial subpopulation during chronic treatment. RNAi knockdown of CXCR7 inhibited proliferation in trametinib-resistant cells. Thus, adaptive resistance to chronic trametinib treatment contributes to proliferation in the presence of the drug. Acquired amplification of KRAS following trametinib dose escalation further contributed to POS cell proliferation. Adaptive followed by acquired gene expression changes contributed to proliferation in trametinib-resistant cells, suggesting inhibition of early transcriptional reprogramming could prevent resistance and the bypass of targeted therapy.Implications:We defined the differential responses to trametinib in subpopulations of a clinically relevant in vitro model of TNBC, and identified both adaptive and acquired elements that contribute to the emergence of drug resistance mediated by increased expression of CXCR7 and amplification of KRAS.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer
Triple-negative breast cancers contain a spectrum of epithelial and mesenchymal phenotypes. SUM-229PE cells represent a model for this heterogeneity, maintaining both epithelial and mesenchymal subpopulations that are genomically similar but distinct in gene expression profiles. We identified differential regions of open chromatin in epithelial and mesenchymal cells that were strongly correlated with regions of H3K27ac. Motif analysis of these regions identified consensus sequences for transcription factors that regulate cell identity. Treatment with the MEK inhibitor trametinib induced enhancer remodeling that is associated with transcriptional regulation of genes in epithelial and mesenchymal cells. Motif analysis of enhancer peaks downregulated in response to chronic treatment with trametinib identified AP-1 motif enrichment in both epithelial and mesenchymal subpopulations. Chromatin immunoprecipitation sequencing (ChIP-seq) of JUNB identified subpopulation-specific localization, which was significantly enriched at regions of open chromatin. These results indicate that cell identity controls localization of transcription factors and chromatin-modifying enzymes to enhancers for differential control of gene expression. We identified increased H3K27ac at an enhancer region proximal to CXCR7, a G-protein–coupled receptor that increased 15-fold in expression in the epithelial subpopulation during chronic treatment. RNAi knockdown of CXCR7 inhibited proliferation in trametinib-resistant cells. Thus, adaptive resistance to chronic trametinib treatment contributes to proliferation in the presence of the drug. Acquired amplification of KRAS following trametinib dose escalation further contributed to POS cell proliferation. Adaptive followed by acquired gene expression changes contributed to proliferation in trametinib-resistant cells, suggesting inhibition of early transcriptional reprogramming could prevent resistance and the bypass of targeted therapy.Implications:We defined the differential responses to trametinib in subpopulations of a clinically relevant in vitro model of TNBC, and identified both adaptive and acquired elements that contribute to the emergence of drug resistance mediated by increased expression of CXCR7 and amplification of KRAS.